AxoGen (AXGN) Financials

$10.90 -0.06 (-0.55%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$10.91 +0.01 (+0.09%)

As of 05/29/2025 04:56 PM Eastern

Annual Income Statements for AxoGen

This table shows AxoGen's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-9.96	-22	-29
Consolidated Net Income / (Loss)	-9.96	-22	-29
Net Income / (Loss) Continuing Operations	-9.96	-22	-29
Total Pre-Tax Income	-9.96	-22	-29
Total Operating Income	-3.29	-21	-30
Total Gross Profit	142	122	109
Total Revenue	187	159	139
Operating Revenue	187	159	139
Total Cost of Revenue	45	37	30
Operating Cost of Revenue	45	37	30
Total Operating Expenses	145	143	139
Selling, General & Admin Expense	39	38	41
Marketing Expense	78	78	72
Research & Development Expense	28	27	26
Total Other Income / (Expense), net	-6.68	-0.25	0.76
Interest Expense	8.21	2.84	0.62
Interest & Investment Income	1.14	1.49	0.57
Other Income / (Expense), net	0.39	1.09	0.81
Basic Earnings per Share	($0.23)	($0.51)	($0.69)
Weighted Average Basic Shares Outstanding	44.26M	42.88M	42.08M
Diluted Earnings per Share	($0.23)	($0.51)	($0.69)
Weighted Average Diluted Shares Outstanding	44.26M	42.88M	42.08M
Weighted Average Basic & Diluted Shares Outstanding	44.34M	43.21M	42.60M

This table shows AxoGen's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	0.45	-1.86	-1.92	-6.64	-3.89	-4.09	-6.66	-7.07	-5.42	-4.32
Consolidated Net Income / (Loss)	0.45	-1.86	-1.92	-6.64	-3.89	-4.09	-6.66	-7.07	-5.42	-4.32
Net Income / (Loss) Continuing Operations	0.45	-1.86	-1.92	-6.64	-3.89	-4.09	-6.66	-7.07	-5.38	-4.32
Total Pre-Tax Income	0.45	-1.86	-1.92	-6.64	-3.89	-4.09	-6.66	-7.07	-5.38	-4.32
Total Operating Income	2.02	-0.32	-0.43	-4.56	-3.19	-4.03	-6.90	-7.34	-5.61	-4.86
Total Gross Profit	38	36	35	33	32	32	30	28	24	31
Total Revenue	49	49	48	41	43	41	38	37	36	37
Operating Revenue	49	49	48	41	43	41	38	37	36	37
Total Cost of Revenue	12	12	13	8.76	11	9.57	8.50	8.17	12	6.18
Operating Cost of Revenue	12	12	13	8.76	11	9.57	8.50	8.17	12	6.18
Total Operating Expenses	36	37	36	37	35	36	37	36	30	36
Selling, General & Admin Expense	8.83	11	9.42	9.96	7.93	9.87	11	10	13	8.80
Marketing Expense	20	19	20	20	20	19	19	19	12	20
Research & Development Expense	6.70	7.00	6.66	7.41	7.18	6.69	7.14	6.33	5.28	7.05
Total Other Income / (Expense), net	-1.57	-1.54	-1.49	-2.08	-0.70	-0.06	0.24	0.27	0.19	0.54
Interest Expense	1.80	1.89	2.19	2.33	1.84	0.83	0.15	0.02	-0.04	0.06
Interest & Investment Income	0.24	0.39	0.23	0.29	0.34	0.37	0.24	0.55	-	0.19
Weighted Average Basic Shares Outstanding	44.26M	43.88M	43.71M	43.23M	42.88M	43.02M	42.86M	42.57M	42.08M	42.22M
Weighted Average Diluted Shares Outstanding	44.26M	43.88M	43.71M	43.23M	42.88M	43.02M	42.86M	42.57M	42.08M	42.22M
Weighted Average Basic & Diluted Shares Outstanding	44.34M	44.01M	43.83M	43.70M	43.21M	43.04M	42.98M	42.83M	42.60M	42.29M

This table details how cash moves in and out of AxoGen's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-3.47	15	-17
Net Cash From Operating Activities	4.54	-5.72	-16
Net Cash From Continuing Operating Activities	4.54	-5.72	-16
Net Income / (Loss) Continuing Operations	-9.96	-22	-29
Consolidated Net Income / (Loss)	-9.96	-22	-29
Depreciation Expense	6.47	4.22	2.83
Amortization Expense	2.26	2.23	2.92
Non-Cash Adjustments To Reconcile Net Income	15	11	13
Changes in Operating Assets and Liabilities, net	-8.86	-1.16	-5.95
Net Cash From Investing Activities	-10	19	-3.20
Net Cash From Continuing Investing Activities	-10	19	-3.20
Purchase of Property, Plant & Equipment	-3.10	-14	-20
Acquisitions	-1.42	-1.05	-1.18
Purchase of Investments	-5.77	-10	-39
Sale and/or Maturity of Investments	0.00	44	57
Net Cash From Financing Activities	2.29	1.95	1.79
Net Cash From Continuing Financing Activities	2.29	1.95	1.79
Repayment of Debt	-0.01	-0.01	-0.01
Issuance of Common Equity	2.30	1.96	1.81
Cash Interest Paid	7.30	1.94	0.00

This table details how cash moves in and out of AxoGen's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	8.89	-0.53	3.48	-15	-0.07	7.63	16	-7.58	0.97	2.50
Net Cash From Operating Activities	8.74	3.90	4.17	-12	-0.21	1.63	0.29	-7.42	1.36	-0.69
Net Cash From Continuing Operating Activities	8.74	3.90	4.17	-12	-0.21	1.63	0.29	-7.42	1.36	-0.69
Net Income / (Loss) Continuing Operations	0.45	-1.86	-1.92	-6.64	-3.89	-4.09	-6.66	-7.07	-5.42	-4.32
Consolidated Net Income / (Loss)	0.45	-1.86	-1.92	-6.64	-3.89	-4.09	-6.66	-7.07	-5.42	-4.32
Depreciation Expense	1.64	1.65	1.66	1.52	1.56	1.15	0.80	0.71	0.65	0.76
Amortization Expense	0.50	0.54	0.63	0.60	0.52	0.48	0.47	0.75	0.75	0.74
Non-Cash Adjustments To Reconcile Net Income	3.14	2.11	5.28	4.11	0.26	2.69	5.28	2.49	2.14	3.28
Changes in Operating Assets and Liabilities, net	3.01	1.46	-1.48	-12	1.34	1.40	0.40	-4.30	3.25	-1.15
Net Cash From Investing Activities	-0.81	-5.00	-1.23	-3.25	-0.28	5.99	14	-0.79	-1.21	2.97
Net Cash From Continuing Investing Activities	-0.81	-5.00	-1.23	-3.25	-0.28	5.99	14	-0.79	-1.21	2.97
Purchase of Property, Plant & Equipment	-0.67	-0.60	-0.91	-0.92	-1.46	-3.69	-4.42	-4.30	-6.62	-4.37
Acquisitions	-0.14	-0.54	-0.32	-0.42	-0.31	-0.22	-0.26	-0.25	-0.15	-0.18
Net Cash From Financing Activities	0.97	0.57	0.54	0.20	0.42	0.01	0.90	0.63	0.81	0.22
Net Cash From Continuing Financing Activities	0.97	0.57	0.54	0.20	0.42	0.01	0.90	0.63	0.81	0.22
Repayment of Debt	-0.00	-0.00	-0.00	-0.00	-0.00	0.01	-0.01	-0.00	-0.00	-0.01
Issuance of Common Equity	0.97	0.57	0.55	0.21	0.42	-	0.91	0.63	0.82	0.22
Cash Interest Paid	1.57	1.98	2.10	1.66	1.62	0.33	-	0.00	-	-

This table presents AxoGen's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	204	197	195
Total Current Assets	99	88	98
Cash & Equivalents	28	31	15
Restricted Cash	6.00	6.00	6.25
Short-Term Investments	5.93	0.00	34
Accounts Receivable	24	25	22
Inventories, net	33	23	19
Prepaid Expenses	2.45	2.81	1.94
Plant, Property, & Equipment, net	85	89	79
Total Noncurrent Assets	20	20	18
Intangible Assets	5.58	4.53	3.65
Other Noncurrent Operating Assets	14	16	14
Total Liabilities & Shareholders' Equity	204	197	195
Total Liabilities	100	101	94
Total Current Liabilities	31	30	24
Accounts Payable	29	29	22
Other Current Liabilities	1.97	1.55	1.31
Total Noncurrent Liabilities	69	71	71
Long-Term Debt	47	47	46
Capital Lease Obligations	19	21	20
Other Noncurrent Operating Liabilities	2.49	2.99	4.52
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	104	96	101
Total Preferred & Common Equity	104	96	101
Total Common Equity	104	96	101
Common Stock	395	377	361
Retained Earnings	-291	-281	-260

This table presents AxoGen's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	192	189	187	195	192	189	196
Total Current Assets	86	82	79	87	86	89	102
Cash & Equivalents	19	19	16	31	23	7.71	14
Restricted Cash	6.00	6.00	6.00	6.00	6.25	6.25	6.25
Short-Term Investments	5.87	1.94	1.92	1.49	11	30	39
Accounts Receivable	25	25	24	23	22	22	21
Inventories, net	29	28	28	23	21	20	19
Prepaid Expenses	1.73	1.96	3.18	2.57	2.58	2.45	2.61
Plant, Property, & Equipment, net	86	87	88	89	87	83	75
Total Noncurrent Assets	20	20	20	18	18	18	18
Intangible Assets	5.22	4.97	4.77	4.29	4.05	3.86	3.45
Other Noncurrent Operating Assets	15	15	15	14	14	14	15
Total Liabilities & Shareholders' Equity	192	189	187	195	192	189	196
Total Liabilities	93	93	93	97	94	92	94
Total Current Liabilities	23	23	23	27	24	21	24
Accounts Payable	21	22	21	26	23	20	22
Other Current Liabilities	1.86	1.75	1.64	1.10	1.04	1.05	1.53
Total Noncurrent Liabilities	70	70	70	70	71	71	71
Long-Term Debt	47	47	47	46	46	46	45
Capital Lease Obligations	20	20	21	-	-	-	-
Other Noncurrent Operating Liabilities	2.54	2.55	2.92	24	24	25	25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	99	96	93	98	97	98	101
Total Preferred & Common Equity	99	96	93	98	97	98	101
Total Common Equity	99	96	93	98	97	98	101
Common Stock	391	386	381	375	370	364	356
Retained Earnings	-292	-290	-288	-277	-273	-267	-254

This table displays calculated financial ratios and metrics derived from AxoGen's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	17.81%	14.74%	8.81%
EBITDA Growth	141.88%	39.85%	-14.88%
EBIT Growth	85.77%	29.51%	-12.33%
NOPAT Growth	84.68%	27.75%	-16.88%
Net Income Growth	54.12%	24.98%	-7.27%
EPS Growth	54.90%	26.09%	-6.15%
Operating Cash Flow Growth	179.34%	64.42%	-19.85%
Free Cash Flow Firm Growth	75.93%	34.88%	-11.53%
Invested Capital Growth	3.76%	12.77%	27.60%
Revenue Q/Q Growth	3.58%	4.44%	3.45%
EBITDA Q/Q Growth	326.24%	22.97%	-2.90%
EBIT Q/Q Growth	60.29%	14.55%	-1.70%
NOPAT Q/Q Growth	61.32%	10.11%	-0.87%
Net Income Q/Q Growth	30.36%	6.55%	-0.45%
EPS Q/Q Growth	25.81%	10.53%	-1.47%
Operating Cash Flow Q/Q Growth	202.81%	-37.97%	15.18%
Free Cash Flow Firm Q/Q Growth	80.52%	15.57%	-0.71%
Invested Capital Q/Q Growth	-3.49%	19.68%	27.98%
Profitability Metrics	-	-	-
Gross Margin	75.79%	76.64%	78.51%
EBITDA Margin	3.11%	-8.76%	-16.70%
Operating Margin	-1.75%	-13.50%	-21.44%
EBIT Margin	-1.55%	-12.81%	-20.85%
Profit (Net Income) Margin	-5.32%	-13.66%	-20.89%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	343.70%	106.62%	100.19%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-1.79%	-12.60%	-20.80%
ROIC Less NNEP Spread (ROIC-NNEP)	-28.23%	-44.63%	98.73%
Return on Net Nonoperating Assets (RNNOA)	-8.20%	-9.48%	-6.31%
Return on Equity (ROE)	-9.99%	-22.08%	-27.11%
Cash Return on Invested Capital (CROIC)	-5.48%	-24.60%	-45.06%
Operating Return on Assets (OROA)	-1.45%	-10.39%	-14.32%
Return on Assets (ROA)	-4.98%	-11.07%	-14.35%
Return on Common Equity (ROCE)	-9.99%	-22.08%	-27.11%
Return on Equity Simple (ROE_SIMPLE)	-9.59%	-22.70%	-28.66%
Net Operating Profit after Tax (NOPAT)	-2.30	-15	-21
NOPAT Margin	-1.23%	-9.45%	-15.01%
Net Nonoperating Expense Percent (NNEP)	26.45%	32.03%	-119.54%
Return On Investment Capital (ROIC_SIMPLE)	-1.35%	-9.19%	-12.44%
Cost of Revenue to Revenue	24.21%	23.36%	21.49%
SG&A Expenses to Revenue	20.84%	24.16%	29.52%
R&D to Revenue	14.82%	17.19%	18.49%
Operating Expenses to Revenue	77.54%	90.14%	99.95%
Earnings before Interest and Taxes (EBIT)	-2.90	-20	-29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	5.83	-14	-23
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	6.98	3.07	4.18
Price to Tangible Book Value (P/TBV)	7.38	3.23	4.34
Price to Revenue (P/Rev)	3.87	1.85	3.05
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.74	2.57	3.86
Enterprise Value to Revenue (EV/Rev)	4.02	2.04	3.13
Enterprise Value to EBITDA (EV/EBITDA)	129.05	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	165.93	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.64	0.71	0.65
Long-Term Debt to Equity	0.64	0.71	0.65
Financial Leverage	0.29	0.21	-0.06
Leverage Ratio	2.01	1.99	1.89
Compound Leverage Factor	6.90	2.13	1.89
Debt to Total Capital	39.10%	41.46%	39.56%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	39.10%	41.46%	39.56%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.90%	58.54%	60.44%
Debt to EBITDA	11.44	-4.87	-2.86
Net Debt to EBITDA	4.67	-2.21	-0.48
Long-Term Debt to EBITDA	11.44	-4.87	-2.86
Debt to NOPAT	-29.00	-4.51	-3.18
Net Debt to NOPAT	-11.84	-2.04	-0.53
Long-Term Debt to NOPAT	-29.00	-4.51	-3.18
Altman Z-Score	3.63	0.56	1.50
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.24	2.89	4.13
Quick Ratio	1.88	1.85	2.99
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-7.06	-29	-45
Operating Cash Flow to CapEx	146.24%	-41.21%	-80.02%
Free Cash Flow to Firm to Interest Expense	-0.86	-10.35	-72.18
Operating Cash Flow to Interest Expense	0.55	-2.02	-25.75
Operating Cash Flow Less CapEx to Interest Expense	0.17	-6.91	-57.92
Efficiency Ratios	-	-	-
Asset Turnover	0.94	0.81	0.69
Accounts Receivable Turnover	7.61	6.72	6.87
Inventory Turnover	1.61	1.77	1.67
Fixed Asset Turnover	2.16	1.89	1.95
Accounts Payable Turnover	1.58	1.45	1.33
Days Sales Outstanding (DSO)	47.98	54.32	53.13
Days Inventory Outstanding (DIO)	226.12	206.00	218.19
Days Payable Outstanding (DPO)	231.44	252.19	275.22
Cash Conversion Cycle (CCC)	42.67	8.13	-3.90
Capital & Investment Metrics	-	-	-
Invested Capital	131	126	112
Invested Capital Turnover	1.45	1.33	1.39
Increase / (Decrease) in Invested Capital	4.76	14	24
Enterprise Value (EV)	752	325	433
Market Capitalization	725	294	422
Book Value per Share	$2.36	$2.22	$2.39
Tangible Book Value per Share	$2.23	$2.12	$2.30
Total Capital	171	163	167
Total Debt	67	68	66
Total Long-Term Debt	67	68	66
Net Debt	27	31	11
Capital Expenditures (CapEx)	3.10	14	20
Debt-free, Cash-free Net Working Capital (DFCFNWC)	29	21	19
Debt-free Net Working Capital (DFNWC)	69	58	74
Net Working Capital (NWC)	69	58	74
Net Nonoperating Expense (NNE)	7.66	6.69	8.15
Net Nonoperating Obligations (NNO)	27	31	11
Total Depreciation and Amortization (D&A)	8.73	6.44	5.74
Debt-free, Cash-free Net Working Capital to Revenue	15.55%	12.92%	13.91%
Debt-free Net Working Capital to Revenue	36.62%	36.21%	53.63%
Net Working Capital to Revenue	36.62%	36.21%	53.63%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.23)	($0.51)	($0.69)
Adjusted Weighted Average Basic Shares Outstanding	44.26M	42.88M	42.08M
Adjusted Diluted Earnings per Share	($0.23)	($0.51)	($0.69)
Adjusted Weighted Average Diluted Shares Outstanding	44.26M	42.88M	42.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.34M	43.21M	42.60M
Normalized Net Operating Profit after Tax (NOPAT)	-2.30	-15	-21
Normalized NOPAT Margin	-1.23%	-9.45%	-15.01%
Pre Tax Income Margin	-5.32%	-13.66%	-20.89%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-0.35	-7.18	-46.30
NOPAT to Interest Expense	-0.28	-5.30	-33.33
EBIT Less CapEx to Interest Expense	-0.73	-12.08	-78.48
NOPAT Less CapEx to Interest Expense	-0.66	-10.19	-65.50
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from AxoGen's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	15.10%	17.86%	25.57%	12.86%	18.69%	11.67%	10.74%	18.24%	14.67%	18.44%
EBITDA Growth	1,453.75%	192.09%	142.35%	59.59%	93.11%	32.17%	10.11%	36.36%	-17.13%	45.68%
EBIT Growth	184.57%	90.33%	100.55%	39.50%	59.24%	18.32%	10.32%	31.31%	-9.00%	34.09%
NOPAT Growth	190.21%	92.15%	93.80%	37.88%	43.05%	17.10%	12.90%	35.15%	-4.76%	27.42%
Net Income Growth	111.56%	54.56%	71.16%	6.21%	28.11%	5.30%	13.95%	38.35%	-2.44%	39.53%
EPS Growth	0.00%	60.00%	75.00%	11.76%	42.86%	0.00%	11.11%	37.04%	-7.69%	41.18%
Operating Cash Flow Growth	4,239.81%	139.91%	1,326.37%	-65.24%	-115.49%	335.99%	105.13%	32.83%	189.96%	-83.24%
Free Cash Flow Firm Growth	83.43%	-46.35%	-36.15%	-39.86%	41.27%	24.21%	-164.32%	-274.40%	-6.96%	-22,885.83%
Invested Capital Growth	3.76%	28.68%	32.49%	37.96%	12.77%	20.59%	24.01%	32.04%	27.60%	37.98%
Revenue Q/Q Growth	1.56%	1.53%	15.79%	-3.60%	4.00%	8.17%	4.07%	1.38%	-2.15%	7.27%
EBITDA Q/Q Growth	125.99%	-20.70%	193.40%	-708.79%	84.63%	63.53%	10.87%	-37.82%	-51.43%	51.67%
EBIT Q/Q Growth	674.64%	-1,048.65%	100.80%	-92.96%	34.28%	46.21%	11.31%	-29.99%	-31.71%	40.94%
NOPAT Q/Q Growth	1,011.84%	26.17%	90.61%	-42.77%	20.65%	41.68%	5.98%	-30.90%	-15.51%	38.73%
Net Income Q/Q Growth	124.22%	3.28%	71.05%	-70.43%	4.79%	38.60%	5.85%	-30.64%	-25.41%	44.21%
EPS Q/Q Growth	0.00%	0.00%	73.33%	-87.50%	20.00%	37.50%	5.88%	-21.43%	-40.00%	44.44%
Operating Cash Flow Q/Q Growth	123.92%	-6.34%	133.96%	-5,713.27%	-112.98%	456.85%	103.93%	-645.01%	297.68%	87.89%
Free Cash Flow Firm Q/Q Growth	91.01%	9.23%	17.82%	-147.19%	20.63%	15.56%	15.58%	-3.80%	-2.43%	-194.50%
Invested Capital Q/Q Growth	-3.49%	0.04%	-0.87%	8.42%	19.68%	3.00%	3.22%	-11.38%	27.98%	5.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	76.05%	74.91%	73.77%	78.83%	74.60%	76.82%	77.71%	77.71%	67.46%	83.29%
EBITDA Margin	8.41%	3.78%	4.84%	-6.00%	-0.72%	-4.84%	-14.35%	-16.76%	-12.33%	-7.97%
Operating Margin	4.08%	-0.65%	-0.89%	-11.02%	-7.44%	-9.75%	-18.09%	-20.02%	-15.51%	-13.14%
EBIT Margin	4.08%	-0.72%	0.08%	-11.12%	-5.56%	-8.79%	-17.68%	-20.75%	-16.18%	-12.02%
Profit (Net Income) Margin	0.91%	-3.82%	-4.01%	-16.04%	-9.07%	-9.91%	-17.46%	-19.29%	-14.97%	-11.68%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.59%	100.00%
Interest Burden Percent	22.31%	529.34%	-5,191.89%	144.18%	163.23%	112.68%	98.71%	92.99%	91.99%	97.19%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	5.94%	-0.68%	-0.91%	-10.69%	-6.95%	-10.76%	-20.23%	-23.16%	-15.05%	-16.31%
ROIC Less NNEP Spread (ROIC-NNEP)	0.53%	-8.08%	-8.03%	-25.76%	-14.88%	31.02%	6.56%	-8.73%	6.79%	-13.51%
Return on Net Nonoperating Assets (RNNOA)	0.15%	-1.81%	-1.90%	-6.17%	-3.16%	-0.95%	-0.45%	1.16%	-0.43%	4.10%
Return on Equity (ROE)	6.09%	-2.49%	-2.81%	-16.86%	-10.11%	-11.71%	-20.68%	-22.00%	-15.48%	-12.22%
Cash Return on Invested Capital (CROIC)	-5.48%	-30.01%	-35.12%	-42.97%	-24.60%	-35.97%	-40.12%	-48.25%	-45.06%	-59.22%
Operating Return on Assets (OROA)	3.82%	-0.68%	0.07%	-9.69%	-4.51%	-6.86%	-13.49%	-15.45%	-11.12%	-7.94%
Return on Assets (ROA)	0.85%	-3.57%	-3.66%	-13.97%	-7.35%	-7.73%	-13.32%	-14.36%	-10.29%	-7.72%
Return on Common Equity (ROCE)	6.09%	-2.49%	-2.81%	-16.86%	-10.11%	-11.71%	-20.68%	-22.00%	-15.48%	-12.22%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-14.39%	-17.28%	-22.84%	0.00%	-23.76%	-24.15%	-25.17%	0.00%	-28.41%
Net Operating Profit after Tax (NOPAT)	2.02	-0.22	-0.30	-3.19	-2.24	-2.82	-4.83	-5.14	-3.93	-3.40
NOPAT Margin	4.08%	-0.45%	-0.63%	-7.71%	-5.21%	-6.83%	-12.66%	-14.02%	-10.86%	-9.20%
Net Nonoperating Expense Percent (NNEP)	5.41%	7.40%	7.12%	15.07%	7.93%	-41.78%	-26.79%	-14.43%	-21.84%	-2.80%
Return On Investment Capital (ROIC_SIMPLE)	1.18%	-	-	-	-1.37%	-	-	-	-2.35%	-
Cost of Revenue to Revenue	23.95%	25.09%	26.23%	21.17%	25.40%	23.18%	22.29%	22.29%	32.54%	16.71%
SG&A Expenses to Revenue	17.87%	22.27%	19.65%	24.06%	18.48%	23.92%	27.65%	27.44%	36.19%	23.80%
R&D to Revenue	13.57%	14.38%	13.90%	17.91%	16.72%	16.22%	18.72%	17.25%	14.60%	19.08%
Operating Expenses to Revenue	71.97%	75.56%	74.66%	89.85%	82.04%	86.57%	95.80%	97.73%	82.96%	96.43%
Earnings before Interest and Taxes (EBIT)	2.02	-0.35	0.04	-4.60	-2.39	-3.63	-6.75	-7.61	-5.85	-4.44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	4.16	1.84	2.32	-2.48	-0.31	-2.00	-5.48	-6.14	-4.46	-2.94
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.98	6.18	3.31	3.74	3.07	2.20	4.03	4.13	4.18	4.97
Price to Tangible Book Value (P/TBV)	7.38	6.52	3.49	3.94	3.23	2.30	4.20	4.30	4.34	5.14
Price to Revenue (P/Rev)	3.87	3.40	1.82	2.13	1.85	1.41	2.64	2.79	3.05	3.76
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	5.74	4.79	2.63	2.86	2.57	2.11	3.87	4.07	3.86	5.60
Enterprise Value to Revenue (EV/Rev)	4.02	3.60	2.06	2.40	2.04	1.46	2.68	2.80	3.13	3.66
Enterprise Value to EBITDA (EV/EBITDA)	129.05	475.86	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	165.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.64	0.67	0.70	0.72	0.71	0.47	0.48	0.47	0.65	0.45
Long-Term Debt to Equity	0.64	0.67	0.70	0.72	0.71	0.47	0.48	0.47	0.65	0.45
Financial Leverage	0.29	0.22	0.24	0.24	0.21	-0.03	-0.07	-0.13	-0.06	-0.30
Leverage Ratio	2.01	1.96	1.97	1.97	1.99	1.96	1.95	1.92	1.89	1.87
Compound Leverage Factor	0.45	10.38	-102.46	2.84	3.26	2.21	1.92	1.79	1.74	1.82
Debt to Total Capital	39.10%	40.26%	41.28%	42.02%	41.46%	32.17%	32.21%	32.02%	39.56%	30.96%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	39.10%	40.26%	41.28%	42.02%	41.46%	32.17%	32.21%	32.02%	39.56%	30.96%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	60.90%	59.74%	58.72%	57.98%	58.54%	67.84%	67.79%	67.98%	60.44%	69.04%
Debt to EBITDA	11.44	48.98	-27.26	-6.58	-4.87	-2.57	-2.43	-2.34	-2.86	-2.02
Net Debt to EBITDA	4.67	26.66	-16.27	-4.27	-2.21	-0.43	-0.28	-0.09	-0.48	0.62
Long-Term Debt to EBITDA	11.44	48.98	-27.26	-6.58	-4.87	-2.57	-2.43	-2.34	-2.86	-2.02
Debt to NOPAT	-29.00	-11.26	-7.87	-5.16	-4.51	-2.77	-2.67	-2.55	-3.18	-2.21
Net Debt to NOPAT	-11.84	-6.13	-4.70	-3.36	-2.04	-0.47	-0.31	-0.10	-0.53	0.67
Long-Term Debt to NOPAT	-29.00	-11.26	-7.87	-5.16	-4.51	-2.77	-2.67	-2.55	-3.18	-2.21
Altman Z-Score	3.71	3.19	1.18	1.23	0.86	0.43	1.53	1.71	1.89	2.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.24	3.74	3.51	3.43	2.89	3.28	3.60	4.18	4.13	4.35
Quick Ratio	1.88	2.13	1.98	1.82	1.85	2.10	2.34	2.83	2.99	3.16
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2.74	-31	-34	-41	-17	-21	-25	-29	-28	-28
Operating Cash Flow to CapEx	1,303.73%	653.43%	457.69%	-1,327.49%	-14.42%	44.07%	6.61%	-172.47%	20.57%	-15.77%
Free Cash Flow to Firm to Interest Expense	-1.52	-16.12	-15.38	-17.58	-8.97	-25.21	-166.79	-1,827.54	0.00	-450.86
Operating Cash Flow to Interest Expense	4.85	2.06	1.91	-5.27	-0.11	1.97	1.97	-463.94	0.00	-11.30
Operating Cash Flow Less CapEx to Interest Expense	4.48	1.75	1.49	-5.67	-0.91	-2.50	-27.86	-732.94	0.00	-82.93
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.94	0.94	0.91	0.87	0.81	0.78	0.76	0.74	0.69	0.66
Accounts Receivable Turnover	7.61	7.55	7.43	7.04	6.72	6.82	7.05	7.06	6.87	6.71
Inventory Turnover	1.61	1.47	1.45	1.34	1.77	1.54	1.43	1.44	1.67	1.36
Fixed Asset Turnover	2.16	2.07	1.99	1.92	1.89	1.86	1.87	1.92	1.95	2.04
Accounts Payable Turnover	1.58	1.64	1.61	1.53	1.45	1.36	1.30	1.30	1.33	1.07
Days Sales Outstanding (DSO)	47.98	48.33	49.15	51.82	54.32	53.49	51.74	51.71	53.13	54.40
Days Inventory Outstanding (DIO)	226.12	248.78	251.16	273.17	206.00	237.46	254.68	253.91	218.19	269.22
Days Payable Outstanding (DPO)	231.44	221.92	227.22	238.60	252.19	268.07	281.57	279.89	275.22	340.34
Cash Conversion Cycle (CCC)	42.67	75.18	73.10	86.39	8.13	22.88	24.85	25.73	-3.90	-16.73
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	131	136	136	137	126	106	103	99	112	88
Invested Capital Turnover	1.45	1.50	1.46	1.39	1.33	1.58	1.60	1.65	1.39	1.77
Increase / (Decrease) in Invested Capital	4.76	30	33	38	14	18	20	24	24	24
Enterprise Value (EV)	752	651	357	393	325	223	396	404	433	490
Market Capitalization	725	614	316	349	294	215	391	403	422	504
Book Value per Share	$2.36	$2.27	$2.19	$2.16	$2.22	$2.28	$2.27	$2.29	$2.39	$2.40
Tangible Book Value per Share	$2.23	$2.15	$2.08	$2.05	$2.12	$2.18	$2.17	$2.20	$2.30	$2.32
Total Capital	171	166	163	161	163	144	143	143	167	147
Total Debt	67	67	67	68	68	46	46	46	66	45
Total Long-Term Debt	67	67	67	68	68	46	46	46	66	45
Net Debt	27	36	40	44	31	7.79	5.37	1.81	11	-14
Capital Expenditures (CapEx)	0.67	0.60	0.91	0.92	1.46	3.69	4.42	4.30	6.62	4.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)	29	33	32	32	21	22	21	23	19	20
Debt-free Net Working Capital (DFNWC)	69	63	59	56	58	61	62	67	74	79
Net Working Capital (NWC)	69	63	59	56	58	61	62	67	74	79
Net Nonoperating Expense (NNE)	1.57	1.64	1.62	3.44	1.66	1.27	1.83	1.94	1.49	0.92
Net Nonoperating Obligations (NNO)	27	36	40	44	31	7.79	5.37	1.81	11	-14
Total Depreciation and Amortization (D&A)	2.14	2.19	2.28	2.12	2.08	1.63	1.27	1.46	1.39	1.50
Debt-free, Cash-free Net Working Capital to Revenue	15.55%	18.07%	18.28%	19.60%	12.92%	14.58%	14.51%	16.18%	13.91%	14.59%
Debt-free Net Working Capital to Revenue	36.62%	34.96%	33.92%	34.04%	36.21%	39.93%	42.07%	46.77%	53.63%	58.90%
Net Working Capital to Revenue	36.62%	34.96%	33.92%	34.04%	36.21%	39.93%	42.07%	46.77%	53.63%	58.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.04)	($0.04)	($0.15)	($0.08)	($0.10)	($0.16)	($0.17)	($0.14)	($0.10)
Adjusted Weighted Average Basic Shares Outstanding	44.26M	43.88M	43.71M	43.23M	42.88M	43.02M	42.86M	42.57M	42.08M	42.22M
Adjusted Diluted Earnings per Share	$0.00	($0.04)	($0.04)	($0.15)	($0.08)	($0.10)	($0.16)	($0.17)	($0.14)	($0.10)
Adjusted Weighted Average Diluted Shares Outstanding	44.26M	43.88M	43.71M	43.23M	42.88M	43.02M	42.86M	42.57M	42.08M	42.22M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	44.34M	44.01M	43.83M	43.70M	43.21M	43.04M	42.98M	42.83M	42.60M	42.29M
Normalized Net Operating Profit after Tax (NOPAT)	1.41	-0.22	-0.30	-3.19	-2.24	-2.82	-4.83	-5.14	-3.93	-3.40
Normalized NOPAT Margin	2.86%	-0.45%	-0.63%	-7.71%	-5.21%	-6.83%	-12.66%	-14.02%	-10.86%	-9.20%
Pre Tax Income Margin	0.91%	-3.82%	-4.01%	-16.04%	-9.07%	-9.91%	-17.46%	-19.29%	-14.89%	-11.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.12	-0.19	0.02	-1.98	-1.29	-4.39	-45.59	-475.44	0.00	-72.84
NOPAT to Interest Expense	1.12	-0.12	-0.14	-1.37	-1.21	-3.41	-32.64	-321.17	0.00	-55.71
EBIT Less CapEx to Interest Expense	0.75	-0.50	-0.40	-2.38	-2.09	-8.85	-75.42	-744.44	0.00	-144.48
NOPAT Less CapEx to Interest Expense	0.75	-0.43	-0.55	-1.77	-2.01	-7.87	-62.48	-590.17	0.00	-127.35
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About AxoGen's Financials

When does AxoGen's fiscal year end?

According to the most recent income statement we have on file, AxoGen's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has AxoGen's net income changed over the last 2 years?

AxoGen's net income appears to be on a downward trend, with a most recent value of -$9.96 million in 2024, falling from -$28.95 million in 2022. The previous period was -$21.72 million in 2023. Find out what analysts predict for AxoGen in the coming months.

What is AxoGen's operating income?

AxoGen's total operating income in 2024 was -$3.29 million, based on the following breakdown:

Total Gross Profit: $141.98 million
Total Operating Expenses: $145.26 million

How has AxoGen revenue changed over the last 2 years?

Over the last 2 years, AxoGen's total revenue changed from $138.58 million in 2022 to $187.34 million in 2024, a change of 35.2%.

How much debt does AxoGen have?

AxoGen's total liabilities were at $99.82 million at the end of 2024, a 1.3% decrease from 2023, and a 5.8% increase since 2022.

How much cash does AxoGen have?

In the past 2 years, AxoGen's cash and equivalents has ranged from $15.28 million in 2022 to $31.02 million in 2023, and is currently $27.55 million as of their latest financial filing in 2024.

How has AxoGen's book value per share changed over the last 2 years?

Over the last 2 years, AxoGen's book value per share changed from 2.39 in 2022 to 2.36 in 2024, a change of -1.1%.

Related Companies

This page (NASDAQ:AXGN) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AxoGen (AXGN) Financials

Frequently Asked Questions About AxoGen's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AxoGen (AXGN) Financials

Annual Income Statements for AxoGen

Quarterly Income Statements for AxoGen

Annual Cash Flow Statements for AxoGen

Quarterly Cash Flow Statements for AxoGen

Annual Balance Sheets for AxoGen

Quarterly Balance Sheets for AxoGen

Annual Metrics And Ratios for AxoGen

Quarterly Metrics And Ratios for AxoGen

Frequently Asked Questions About AxoGen's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools